Andrew P. Crew

4.9k total citations · 3 hit papers
37 papers, 3.5k citations indexed

About

Andrew P. Crew is a scholar working on Molecular Biology, Organic Chemistry and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrew P. Crew has authored 37 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 10 papers in Organic Chemistry and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrew P. Crew's work include Protein Degradation and Inhibitors (20 papers), Ubiquitin and proteasome pathways (11 papers) and Prostate Cancer Treatment and Research (10 papers). Andrew P. Crew is often cited by papers focused on Protein Degradation and Inhibitors (20 papers), Ubiquitin and proteasome pathways (11 papers) and Prostate Cancer Treatment and Research (10 papers). Andrew P. Crew collaborates with scholars based in United States, United Kingdom and Canada. Andrew P. Crew's co-authors include Craig M. Crews, Hanqing Dong, Jing Wang, Yimin Qian, Kanak Raina, Kevin Coleman, James D. Winkler, Martha Altieri, Jing Lü and John Hines and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Andrew P. Crew

37 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

2015 849 citations Jing Lü, Yimin Qian et al. Chemistry & Biology profile →
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

2016 661 citations Kanak Raina, Jing Lü et al. Proceedings of the National Academy of Sciences profile →
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

2017 488 citations George M. Burslem, Blake E. Smith et al. Cell chemical biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew P. Crew United States	21	3.1k	1.2k	967	357	232	37	3.5k
George M. Burslem United States	20	2.8k 0.9×	1.1k 0.9×	699 0.7×	425 1.2×	110 0.5×	54	3.2k
Frank Boschelli United States	28	1.4k 0.4×	581 0.5×	823 0.9×	654 1.8×	128 0.6×	69	2.6k
Jeremy P. Hunt United States	9	1.8k 0.6×	462 0.4×	781 0.8×	213 0.6×	130 0.6×	10	2.7k
Kanak Raina United States	14	2.8k 0.9×	996 0.8×	828 0.9×	166 0.5×	88 0.4×	23	3.0k
Nicholas Kwiatkowski United States	31	3.2k 1.0×	1.5k 1.3×	393 0.4×	273 0.8×	599 2.6×	48	3.9k
Saul Jaime‐Figueroa United States	20	2.7k 0.9×	1.2k 1.0×	814 0.8×	480 1.3×	65 0.3×	27	3.2k
William C. Shakespeare United States	29	1.8k 0.6×	933 0.8×	666 0.7×	816 2.3×	546 2.4×	59	3.2k
Stephen C. Cosenza United States	23	1.1k 0.4×	571 0.5×	296 0.3×	460 1.3×	140 0.6×	55	2.0k
Georg E. Winter Austria	24	3.6k 1.2×	1.1k 0.9×	624 0.6×	199 0.6×	759 3.3×	48	4.3k
Taavi K. Neklesa United States	18	2.0k 0.6×	784 0.7×	380 0.4×	141 0.4×	221 1.0×	25	2.2k

Countries citing papers authored by Andrew P. Crew

Since Specialization

Citations

This map shows the geographic impact of Andrew P. Crew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew P. Crew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew P. Crew more than expected).

Fields of papers citing papers by Andrew P. Crew

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew P. Crew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew P. Crew. The network helps show where Andrew P. Crew may publish in the future.

Co-authorship network of co-authors of Andrew P. Crew

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew P. Crew. A scholar is included among the top collaborators of Andrew P. Crew based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew P. Crew. Andrew P. Crew is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Snyder, Larry, Taavi K. Neklesa, Xin Chen, et al.. (2023). Abstract ND03: Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer. Cancer Research. 83(7_Supplement). ND03–ND03. 12 indexed citations

Alabi, Shanique, Ryan R. Willard, Jing Wang, et al.. (2018). Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. Communications Biology. 1(1). 100–100. 273 indexed citations

Neklesa, Taavi K., Lawrence B. Snyder, Ryan R. Willard, et al.. (2018). An oral androgen receptor PROTAC degrader for prostate cancer.. Journal of Clinical Oncology. 36(6_suppl). 381–381. 14 indexed citations

Sun, Baohua, Warren Fiskus, Yimin Qian, et al.. (2017). BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia. 32(2). 343–352. 136 indexed citations

Burslem, George M., Blake E. Smith, Saul Jaime‐Figueroa, et al.. (2017). The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. Cell chemical biology. 25(1). 67–77.e3. 488 indexed citations breakdown →

Crew, Andrew P., Kanak Raina, Hanqing Dong, et al.. (2017). Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1. Journal of Medicinal Chemistry. 61(2). 583–598. 195 indexed citations

Winkler, Julia, Kanak Raina, Martha Altieri, et al.. (2016). PROTAC BET degraders are more broadly effective than BET inhibitors. European Journal of Cancer. 69. S10–S10. 3 indexed citations

Raina, Kanak, Jing Lü, Yimin Qian, et al.. (2016). PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proceedings of the National Academy of Sciences. 113(26). 7124–7129. 661 indexed citations breakdown →

Lü, Jing, Yimin Qian, Martha Altieri, et al.. (2015). Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chemistry & Biology. 22(6). 755–763. 849 indexed citations breakdown →

10.

Hornberger, Keith R., Xin Chen, Andrew P. Crew, et al.. (2013). Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: Optimization of kinase selectivity and pharmacokinetics. Bioorganic & Medicinal Chemistry Letters. 23(16). 4511–4516. 23 indexed citations

11.

Bhagwat, Shripad V., Prafulla C. Gokhale, Andrew P. Crew, et al.. (2011). Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin. Molecular Cancer Therapeutics. 10(8). 1394–1406. 159 indexed citations

12.

Bhagwat, Shripad V., Andrew P. Crew, Yan Yao, et al.. (2010). Abstract 4487: OSI-027, a potent and selective small molecule mTORC1/mTORC2 kinase inhibitor is mechanistically distinct from rapamycin. Cancer Research. 70(8_Supplement). 4487–4487. 2 indexed citations

13.

Dong, Hanqing, et al.. (2010). Synthetic approaches to 5,7-disubstituted imidazo[5,1-f][1,2,4]triazin-4-amines. Tetrahedron Letters. 51(30). 3899–3901. 3 indexed citations

14.

Wang, Jianxin, Andrew P. Crew, Meizhong Jin, et al.. (2009). Synthesis of Substituted Imidazo[1,5-a]pyrazines via Mono-, Di-, and Directed Remote Metalation Strategies. Organic Letters. 11(22). 5118–5121. 1 indexed citations

15.

Li, An‐Hu, Xin Chen, Matthew Cox, et al.. (2006). A highly effective one-pot synthesis of quinolines from o-nitroarylcarbaldehydes. Organic & Biomolecular Chemistry. 5(1). 61–64. 72 indexed citations

16.

Mulvihill, Mark J., Qunsheng Ji, Patricia Beck, et al.. (2006). 1,3-Disubstituted-imidazo[1,5-a]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(4). 1091–1097. 23 indexed citations

17.

Sutcliffe, Oliver B., R. C. STORR, T. L. Gilchrist, Paul Rafferty, & Andrew P. Crew. (2000). Azafulvenium methides: new extended dipolar systems. Chemical Communications. 675–676. 17 indexed citations

18.

Crew, Andrew P., et al.. (1992). Heterocyclic fused 2,5-dihydrothiophene S,S-dioxides as precursors to heterocyclic o-quinodimethanes. Tetrahedron. 48(37). 8101–8116. 30 indexed citations

19.

Chauhan, Prem M. S., et al.. (1990). Heterocyclic o-xylylenes: Thiazole, oxazole and imidazole analogues. Tetrahedron Letters. 31(10). 1487–1490. 29 indexed citations

20.

Crew, Andrew P., et al.. (1990). The generation of 2,3-dihydro-2,3-bis-(methylene)thiophenes from 4,6-dihydrothieno[3,4-b]thiophene 5,5-dioxides. Tetrahedron Letters. 31(10). 1491–1494. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact